Kurs & Likviditet
|2020-10-09||Ordinarie utdelning DEX 0.00 SEK|
|2019-10-11||Ordinarie utdelning DEX 0.00 SEK|
|2019-05-28||Extra Bolagsstämma 2019|
|2018-10-11||Ordinarie utdelning DEX 0.00 SEK|
|2017-11-10||Ordinarie utdelning DEX 0.00 SEK|
|2016-11-04||Ordinarie utdelning DEX 0.00 SEK|
|2016-09-13||Extra Bolagsstämma 2016|
|2015-11-04||Ordinarie utdelning DEX 0.00 SEK|
|2014-11-28||Ordinarie utdelning DEX 0.00 SEK|
The company's phase IIb study for the treatment of advanced prostate cancer i.e. castration resistant metastatic prostate cancer (mCRPC), can report promising follow-up results as of October 14. Patients are followed for 24 months after discontinuing the OsteoDex treatment. End point is information about whether the patient is alive or deceased (dead/alive). The last patients are reported in June 2020. The results as of October 14 show the following: patients with stable disease (unchanged) regarding skeletal metastasis at the end of treatment, 58% are alive, patients who discontinued the treatment or completed treatment with progressive disease (progressive disease development) 48% are alive, and patients who completed the treatment and had objective regression of skeletal metastasis (reduction of existing skeletal metastases), 86% are alive. The results indicate prolonged survival after OsteoDex treatment.
The complete clinical study report (CSR) from the phase IIb study for OsteoDex was completed in December 2018 and the last patient was completed in June 2018. The study conducted in Sweden, Finland, Estonia and Latvia included 55 well-defined patients with castration-resistant prostate cancer with skeletal metastases (mCRPC).
The results obtained show that OsteoDex acts as a brake medicine for metastatic castration-resistant prostate cancer. The OsteoDex treatment slowed down the course of the disease in the skeleton of the majority of patients who underwent the entire treatment (5 months) and the study also confirmed a high tolerability of the patients for OsteoDex without serious side effects.
"- The results are a clear indication that the OsteoDex treatment has a positive impact on survival, which is the very purpose of the treatment and is undoubtedly a strong argument in our negotiations with interested parties," says CEO Anders R Holmberg.
For additional information:
Gösta Lundgren - CFO & Investor Relations
DexTech Medical AB
Telephone: +46 (0) 707104788
This information is information that Dextech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on October 14, 2019.
DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical trial has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as treatment effect on patients who fail on existing drugs. DexTech's goal is to license the respective drug candidate by the latest phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.